Advocate Report: Summer 2012 Susan Leighton Summer 2012 was filled with an abundance of advocacy opportunities including the American Association of Cancer Researchers (AACR) Survivor-Scientist Program, the Drug Information Association (DIA) Fellow Program, OCNA’s National Conference, and the Biennial Cancer Survivorship Research Conference. As I began making the rounds of this year’s events, I truly … Continued
08/23/2012 According to a new study published in Cancer Research, Australian researchers have identified a gene that plays a significant role in the development of high-grade serous ovarian cancer tumors becoming resistant to liposomal doxorubicin (commonly known as Doxil), which is commonly used to treat recurrent ovarian cancer. Investigating the changes in a tumor from … Continued
08/23/2012 Reported online last week in Science Translational Medicine, researchers at MIT and Harvard used nanoparticles to demonstrate the nanoparticles that target a protein called ID4 can reduce ovarian cancer tumors in mice. Researchers hope that this approach could help speed the development of new drugs. As new technology allows researchers to sequence cancer cell … Continued
A study of 637 Japanese women with ovarian, fallopian or primary peritoneal cancer showed that dose dense chemotherapy provided a benefit. The standard of care arm provided chemotherapy every three weeks, the dose dense arm provided one of the drugs every week and the other every three weeks. Women who were on the dose dense … Continued
A study of approximately 2700 women showed that women who used fertility drugs did not have a higher risk of ovarian cancer, except for women who used fertility drugs and never got pregnant. Read the full abstract here.
A small retrospective study of women receiving taxane therapy for breast or ovarian cancer while pregnancy showed no statistically significant outcomes in maternal or fetal health. Read the abstract here
08/09/2012 Research investigating the efficacy of screening women with a two-step screening strategy using CA125 and transvaginal sonogram (TVS) is ongoing, as are efforts to identify better biomarkers to identify the disease. In this context, researchers conducted a study evaluating the hypothetical impact on mortality, as well as the cost effectiveness of screening women at … Continued
THE EVENT WAS HOSTED BY KELLY RIPA, PAULA PATTON, DONNA KARAN AND ARIEL FOXMAN AND PRESENTED BY QVC, COVERGIRL, INSTYLE New York, NY – August 6, 2012– Kelly Ripa, Paula Patton, Donna Karan and Ariel Foxman hosted Ovarian Cancer Research Fund’s (OCRF) 15th annual Super Saturday, presented by QVC, COVERGIRL and InStyle. The event raised … Continued
In early September, the skies over Arkansas will fill with butterflies and balloons to mark the start of National Ovarian Cancer Awareness Month. “It’s a way to kick off the month for survivors and supporters,” says Arkansas Ovarian Cancer Coalition (AROVCC) co-founder and board member Amy Lasseigne. “We hope people in Little Rock will see … Continued
The L.A. Times published an editorial July 29 summing up years of data showing that aggressively screening and treating people for cancer does not always benefit them. The editorial also points out that population based studies may not apply to people with known risk factors, like a family history of breast/ovarian cancer. The editorial also … Continued
According to a study of 186 women with ovarian cancer, women with high levels of emotional support lived longer than women without them. The study also suggests that a high degree of “instrumental support” – that is, tangible assistance – did not have any effect on survival. Read the abstract here
07/19/2012Research published July 16th in the Journal of Clinical Oncology shows that greater social attachment was associated with a lower likelihood of death for ovarian cancer patients. A group of researchers, including senior author and OCRF grantee Anil Sood, MD examined how social support related to long term survival. Two types of social support were … Continued
Get email updates about research news, action alerts, and ways to join the fight.
